BioInvent International AB (publ) (STO:BINV)

Market Cap	1.81B -19.1%
Revenue (ttm)	217.86M +258.3%
Net Income	-335.45M
EPS	-5.10
Shares Out	65.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,447
Average Volume	170,268
Open	27.70
Previous Close	25.65
Day's Range	26.40 - 28.80
52-Week Range	19.22 - 41.60
Beta	-0.05
RSI	70.18
Earnings Date	Aug 27, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat solid tumors; BI-1910, an anti-TNFR2 antibod...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 112
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.